CogState Ltd.   Report issue

For profit Phase 2 Phase 4
Founded: New Haven CT United States (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2013
NCT02146534
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CogState Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

dalfampridine (ampyra) (1 trial)

Drugs in Phase 2 Trials (2)

abx-1431 (1 trial)

nyx-458 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 2)

Disease (Phase 2)

Multiple Sclerosis (Phase 4)

Parkinson Disease (Phase 2)

Syndrome (Phase 2)

Tic Disorders (Phase 2)

Tics (Phase 2)

Tourette Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3